The Impact of Neutralizing Antibody Testing on The Cost-Effectiveness of Injectable Disease Modifying Treatments for Relapsing Remitting Multiple Sclerosis

The Cost ◽

The Impact

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2016.1258366 ◽

2016 ◽

Vol 20 (3) ◽

pp. 297-302 ◽

Cited By ~ 12

Author(s):

Duygu Bozkaya ◽

Terrie Livingston ◽

Kristen Migliaccio-Walle ◽

Tanner Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

The Cost-Effectiveness of Disease Modifying Therapies for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.03.1653 ◽

2015 ◽

Vol 18 (3) ◽

pp. A283 ◽

Cited By ~ 2

Author(s):

D. Bozkaya ◽

T.P. Livingston ◽

K. Migliaccio-Walle ◽

S. Mehta ◽

T. Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

PND73 - THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS: AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM

Value in Health ◽

10.1016/j.jval.2018.09.2039 ◽

2018 ◽

Vol 21 ◽

pp. S341

Author(s):

H Phelps ◽

C Treharne ◽

G Ramirez Guevara ◽

E Bertranou

Keyword(s):

Multiple Sclerosis ◽

United Kingdom ◽

Cost Effectiveness ◽

Subsequent Treatment ◽

The United Kingdom ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Impact

The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Value in Health ◽

10.1016/j.jval.2013.08.1826 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623 ◽

Cited By ~ 2

Author(s):

W. Su ◽

A. Walker ◽

S. Sarda ◽

A.R. Kansal ◽

C. Vicente ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

The Cost ◽

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2009.15.7.543 ◽

2009 ◽

Vol 15 (7) ◽

pp. 543-555 ◽

Cited By ~ 15

Author(s):

Lawrence Goldberg ◽

Natalie C. Edwards ◽

Contessa Fincher ◽

Quan V. Doan ◽

Ahmad AL-Sabbagh ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Line Treatment ◽

First Line ◽

Disease Modifying Drugs ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

First Line Treatment

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Cited By ~ 10

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA

Value in Health ◽

10.1016/s1098-3015(10)64557-3 ◽

2006 ◽

Vol 9 (3) ◽

pp. A81-A82

Author(s):

CF Bell ◽

JB Graham ◽

SR Earnshaw ◽

M Oleen-Burkey ◽

J Castelli-Haley ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

The Cost ◽

Term Data

PND19 A LONG-TERM COST-EFFECTIVENESS MARKOV MODEL COMPARING DISEASE MODIFYING TREATMENTS IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

Value in Health ◽

10.1016/s1098-3015(11)72600-6 ◽

2010 ◽

Vol 13 (7) ◽

pp. A391

Author(s):

C Plesnila-Frank ◽

N Putzki ◽

D Eheberg ◽

V Limmroth ◽

Z Katsarava ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Markov Model ◽

Relapsing Remitting ◽

Disease Modifying ◽

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2011.17.5.377 ◽

2011 ◽

Vol 17 (5) ◽

pp. 377-381 ◽

Cited By ~ 3

Author(s):

Russell V. Becker III ◽

Carole Dembek

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Disease Modifying Drugs ◽

Effectiveness Analysis ◽

Cohort Selection ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study

Advances in Therapy ◽

10.1007/s12325-020-01349-3 ◽

2020 ◽

Vol 37 (6) ◽

pp. 2999-3009

Author(s):

Florian Lenz ◽

Lutz Harms

Keyword(s):

Multiple Sclerosis ◽

Prospective Study ◽

Support Programs ◽

Patient Support ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Impact